Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 9/20 | 0.49 |
| ▸ | KIT | P10721 | 8/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 9/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.46 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.46 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59320 | 0.95 | ACVRL1 (0.51) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL58475 | 0.91 | ACVRL1 (0.50) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL58432 | 0.91 | ACVRL1 (0.51) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL58278 | 0.91 | ACVRL1 (0.54) | ACVRL1KDRKITFLT3FGFR1 | |
| SCHEMBL58841 | 0.91 | ACVRL1 (0.49) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL58935 | 0.91 | ACVRL1 (0.57) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL57574 | 0.90 | RET (0.52) | ACVRL1FLT3FGFR1MAPK9PRKCD | |
| SCHEMBL90954 | 0.88 | ACVRL1 (0.50) | ACVRL1KDRKITTEKFLT3 | |
| SCHEMBL57906 | 0.88 | ACVRL1 (0.51) | ACVRL1KDRKITFLT3FGFR1 | |
| SCHEMBL58423 | 0.87 | ACVRL1 (0.52) | ACVRL1KDRKITFLT3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885KDR 41/4885KIT 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.